

OMB APPROVAL	
OMB Number:	3235-0080
Expires:	May 31, 2024
Estimated average burden hours per response	1.00

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D. C. 20549

FORM 25

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number 001-38746

**Taiwan Liposome Company, Ltd.
The Nasdaq Global Market**

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Carina Chen
Chief Financial Officer
Taiwan Liposome Company, Ltd.
2F, No. 3 Yuanqu Street
Nangang District,
Taipei City, Taiwan 11503
Republic of China
+886 2 2655 7377

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American depositary shares, each representing two common shares, par value NT\$10 per share
(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- 17 CFR 240.12d2-2(a)(1)
- 17 CFR 240.12d2-2(a)(2)
- 17 CFR 240.12d2-2(a)(3)
- 17 CFR 240.12d2-2(a)(4)
- Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Taiwan Liposome Company, Ltd. (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

September 20, 2021
Date

By /s/ Carina Chen
Name

Chief Financial Officer
Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.